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While adenovirus holds many advantages as a vector for gene delivery, much of its full potential has been
limited by the tendency of the most commonly used vectors to target the liver upon systemic delivery, result-
ing in unacceptable toxicity. Recently in Cell, Waddington et al. unmasked the virus-host interactions that
lead to hepatic transduction. The results point a way toward avoiding this pathway during development of
future generations of adenovirus vectors.Since its nascency, the gene therapy field
has looked to the common human patho-
gen, adenovirus, as a vector. Early vec-
tors, although predicted by some to be
unable to replicate, underwent low levels
of replication, leading to removal of trans-
duced cells by a robust adaptive immune
response (Yang et al., 1994). While later
genetic modifications to the vector back-
bone decreased viral gene expression
and, therefore, the ability of the immune
system to recognize the infected cell,
they did not abrogate the stimulation of
an equally powerful innate immune re-
sponse against the infecting viral parti-
cles. Even ultraviolet (UV) light inactivation
of the virus does not prevent the innate
response (McCoy et al., 1995). This issue
became more than an experimental
curiosity with the unfortunate death of
a patient enrolled in a gene therapy trial
for ornithine transcarbamylase deficiency.
In this individual, delivery of a second gen-
eration adenovirus vector directly to the
liver resulted in a massive cytokine storm
that could not be reversed (Raper et al.,
2003).
A significant amount of effort has been
devoted to understanding how the virus
interacts with the host cell, defining both
the cellular receptors and the viral ligands
that engage these receptors. For themost
intensively studied adenovirus, serotype
5 (Ad5), binding to the cell is mediated
by an interaction between the viral fiber
protein, a trimeric structure that extrudes
from each of the 12 vertices of the icosa-
hedral particle, and a molecule called the
coxsackievirus and adenovirus receptor
(CAR). Next, the penton base, from which
the fiber extends, binds alphav integrins,
leading to internalization of the virus. Aspart of an effort to target the virus to other
specific receptors on the cell surface,
domains of the fiber and penton base
that are involved in receptor binding
have been defined and manipulated.
However, mutating these domains or con-
structing chimeric viruses that contain the
fiber protein fromother serotypes has little
or no effect on liver transduction (Nicklin
et al., 2005; Waddington et al., 2007).
Therefore, efforts have been made to de-
fine the viral determinants of targeting to
the liver.
The Lieber and Baker laboratories iden-
tified plasma proteins that can bind the
viral particle and allow it to interact with
cells in the liver, potentially bypassing
CAR. Two of these proteins, coagulation
factor IX (FIX) and complement compo-
nent C4 binding protein (C4BP), bind to
the knob domain of the fiber, a structure
at the particle-distal end of the protein
that mediates the aforementioned inter-
action with CAR (Shayakhmetov et al.,
2005). A third plasma protein, coagulation
factor X (FX), also binds the viral particle
(Parker et al., 2006). Warfarin, which inter-
feres with the function of vitamin K-
dependent coagulation factors, of which
FX is one, reduces liver transduction by
adenoviruses independent of their ability
to bind CAR. The question remained,
then, of what is the binding site for FX on
the adenovirus particle.
Using a combination of biochemical,
genetic, electron microscopic, and phar-
macological approaches, the Baker
group has answered this question (Wad-
dington et al., 2008). The logical guess
as to which viral protein was responsible
for binding was fiber. However, such
a role for fiber was not detectable. TheseCell Host & Microinvestigators therefore turned their atten-
tion to the hexon protein, which is the
most abundant capsid protein, compris-
ing 240 trimers on the surface of the parti-
cle. FXdoes indeedbindhexonspecifically
(Figure 1). Mutational analysis defined two
domains on FX that are important for liver
transduction, a Gla (g-carboxylated gluta-
mic acid) domain that interacts with hexon
and a serine protease domain that binds to
the cell. Using cryoelectron microscopy,
they also visualized the three-dimensional
binding site for FX on the hexons, and
stoichiometric measurements determined
that there is one FX per hexon trimer.
The hexon protein is themajor antigenic
determinant on the adenovirus capsid.
When the hexon protein sequences
from the various human adenovirus sero-
types are aligned, there are conserved
sequences that are important for the
structure of the virus and nonconserved
regions that are surface-exposed and
represent the targets of neutralizing anti-
bodies. The latter regions are called hy-
pervariable regions (HVRs). Interestingly,
Waddington et al. (2008) now demon-
strate that FX interacts with these HVRs.
They also examined FX binding to repre-
sentative hexons from the six adenovirus
species (formerly called subgroups), into
which the 50+ serotypes are classified.
Binding fell into three categories: strong,
weak, or none. All of the adenoviruses
that did not bind are members of species
D, which correlates with a phylogenetic
analysis of the HVRs, showing that this
species probably diverged from species
A, B, and C at an early time. Intravascular
administration of two species D viruses
that do not bind FX, Ad26 and Ad38
resulted in no liver transduction.be 3, March 2008 ª2008 Elsevier Inc. 119
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PreviewsFigure 1. Two Ways for Adenovirus to Interact with Liver Cells
The surface of a liver cell is shown along with two bound adenovirus particles. The particle on the left con-
tacts the cell through a fiber knob-CAR interaction. That on the right contacts the cell through an interac-
tion between the hexons and FX, which is depicted as a bridge. The cellular receptor for this interaction is
not yet known. Illustration by Payam Entezami.As a whole, these studies indicate that
the FX is the major mediator of liver tro-
pism of Ad5 through binding to the hexon
protein. These results have important
implications for the design of safer adeno-
virus vectors. Simply swapping the fiber
protein of Ad5 with that of another sero-
type will not prevent the virus from infect-
ing the liver. Similarly, attempts to modifyA Good Catch: Pa
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In tailed bacteriophages and herpe
shell, through a dedicated channel k
termined the structure of the bacter
identifying structural changes that s
tion into a new host.
Tailed bacteriophages (caudovirales) rep-
resent over 90% of all known viruses of
prokaryotes and are arguably the most
abundant organisms on Earth. Moreover,
it is now clear that they share common
120 Cell Host & Microbe 3, March 2008 ª20the fiber to retarget it to receptors other
than CAR will likely need to be coupled
with changes to the hexon. Ad26, one vi-
rus that does not bind FX, is already under
development as a vector. In addition, Os-
tapchuk and Hearing (2001) have demon-
strated that one can produce Ad5-based
vectors that incorporate hexons from
other serotypes. The stage is set, then,ckaging the Virus G
rch Street, Glasgow G11 5JR, UK
sviruses, double-stranded DNA is pa
nown as the portal. In a recent issue
iophage P22 portal complex in pre-
erve to retain the genome within the
ancestry with Herpesviruses, which are
ubiquitous pathogens in vertebrates, and
it seems likely that an undiscovered gal-
axy of related forms infect other eukary-
otes. It is reasonable to assume, there-
08 Elsevier Inc.for approaches that will improve the
safety of adenovirus as a therapeutic tool.
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of Molecular Cell, Zheng et al. de-
and postpackaging conformations,
virus particle and prime it for injec-
fore, that viruses of the caudovirales
lineage are doing something right, and
one of their strengths seems to lie in their
particle assembly and DNA-packaging
mechanisms.
